About the Data
BEAM is the most comprehensive pharmaceutical pipeline point-in-time data available covering 20 years of history with over 1,000,000 observations of pipeline data for 1,800 pharma/biotech ticker symbols which includes over 10,000 pharmaceutical products. In addition to the breadth and depth of our data, it meets the highest quality standards in the industry delivering higher quality for modeling and reporting capabilities than any other data source available.
- Predict relative stock performance, the likelihood of success, timing, and value impact of company trials with our proprietary data elements for biomarkers, novel status, endpoints, and mechanism of action to support your predictive analytics.
- Compare company pipeline strength and determine ability to win using point-in-time clinical trial data including more than 1,800 ticker symbols mapped to public companies in the pharmaceutical and healthcare industry.
- Make more informed decisions to mitigate risk by leveraging pharmaceutical data. Unlock the biotech and pharmaceutical R&D landscape to power predictive analytics with access to 20+ years of model-ready clinical trial data.
Matrix of Companies Most likely to be Acquired
By applying insights about company pipeline value, we are able to match the top acquisition targets and even provide a compatibility score.
Short Term Investment Portfolio Return
Our additional short-term investment portfolio-based strategy has demonstrated a 30% annualized return on growth, which is twice that of the pharmaceutical and biotech industries overall.
Catalyst Events Related to Clinical Outcomes
No more chasing headlines, our predictions for reported outcomes are best in class for getting ahead of the crowd. Always have a list of expected catalyst events at your fingertips.
Top Pharmaceutical Company Pipeline Value by Disease Area
Company pipeline value available by disease area or phase of development at your fingertips. Use the same data and views the pharmaceutical industry uses for portfolio planning and acquisitions.
